Literature DB >> 20042847

Recurrent TB: relapse or reinfection? The effect of HIV in a general population cohort in Malawi.

Amelia C Crampin1, J Nimrod Mwaungulu, Frank D Mwaungulu, D Totah Mwafulirwa, Kondwani Munthali, Sian Floyd, Paul Em Fine, Judith R Glynn.   

Abstract

OBJECTIVE: To estimate rates of recurrent tuberculosis due to reinfection and relapse, by HIV status, in a general population.
DESIGN: Long-term cohort study in Karonga district, rural Malawi.
METHODS: All tuberculosis patients with culture-proven disease in Karonga district were followed up after treatment. HIV testing was offered and all Mycobacterium tuberculosis isolates were fingerprinted using IS6110 RFLP. Fingerprints from initial and recurrent disease episodes were compared to distinguish relapse and reinfection: a second episode was considered a relapse if the fingerprint was identical or differed by only 1-4 bands and was the first occurrence of that pattern in the population. Rates of and risk factors for recurrence, reinfection disease, and relapse were estimated using survival analysis and Poisson regression.
RESULTS: Five hundred and eighty-four culture-positive episodes of tuberculosis were diagnosed and treatment was completed during 1995-2003 in patients with known HIV status; 53 culture-positive recurrences occurred by May 2005. Paired fingerprints were available for 39 of these. Reinfections accounted for 1/16 recurrences in HIV-negative and 12/23 in HIV-positive individuals. Rates of relapse were similar in HIV-positive and HIV-negative individuals. Using multiple imputation to allow for missing fingerprint information, the rate of reinfection disease in HIV-positive individuals was 2.2/100 person-years, and in HIV-negative individuals 0.4/100 person-years.
CONCLUSIONS: HIV increases the rate of recurrent tuberculosis in this setting by increasing the rate of reinfection disease, not relapse.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20042847      PMCID: PMC2917772          DOI: 10.1097/QAD.0b013e32832f51cf

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  33 in total

1.  Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis.

Authors:  Suzanne Verver; Robin M Warren; Nulda Beyers; Madalene Richardson; Gian D van der Spuy; Martien W Borgdorff; Donald A Enarson; Marcel A Behr; Paul D van Helden
Journal:  Am J Respir Crit Care Med       Date:  2005-04-14       Impact factor: 21.405

2.  Calculation of the stability of the IS6110 banding pattern in patients with persistent Mycobacterium tuberculosis disease.

Authors:  R M Warren; G D van der Spuy; M Richardson; N Beyers; M W Borgdorff; M A Behr; P D van Helden
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

3.  Risk factors for relapse in human immunodeficiency virus type 1 infected adults with pulmonary tuberculosis.

Authors:  J L Johnson; A Okwera; M J Vjecha; F Byekwaso; J Nakibali; S Nyole; J Milberg; T Aisu; C C Whalen; R D Mugerwa; J J Ellner
Journal:  Int J Tuberc Lung Dis       Date:  1997-10       Impact factor: 2.373

4.  Analysis of rate of change of IS6110 RFLP patterns of Mycobacterium tuberculosis based on serial patient isolates.

Authors:  A S de Boer; M W Borgdorff; P E de Haas; N J Nagelkerke; J D van Embden; D van Soolingen
Journal:  J Infect Dis       Date:  1999-10       Impact factor: 5.226

5.  DNA fingerprint changes in tuberculosis: reinfection, evolution, or laboratory error?

Authors:  Judith R Glynn; Malcolm D Yates; Amelia C Crampin; Bagrey M Ngwira; Frank D Mwaungulu; Gillian F Black; Steven D Chaguluka; Donex T Mwafulirwa; Sian Floyd; Caroline Murphy; Francis A Drobniewski; Paul E M Fine
Journal:  J Infect Dis       Date:  2004-08-03       Impact factor: 5.226

6.  Trends and measurement of HIV prevalence in northern Malawi.

Authors:  Amelia C Crampin; Judith R Glynn; Bagrey M Ngwira; Frank D Mwaungulu; Jörg M Pönnighaus; David K Warndorff; Paul E Fine
Journal:  AIDS       Date:  2003-08-15       Impact factor: 4.177

7.  Patients with active tuberculosis often have different strains in the same sputum specimen.

Authors:  Robin M Warren; Thomas C Victor; Elizabeth M Streicher; Madalene Richardson; Nulda Beyers; Nicolaas C Gey van Pittius; Paul D van Helden
Journal:  Am J Respir Crit Care Med       Date:  2003-12-30       Impact factor: 21.405

8.  DNA immunization in a mouse model of latent tuberculosis: effect of DNA vaccination on reactivation of disease and on reinfection with a secondary challenge.

Authors:  Charlene J Repique; Amy Li; Frank M Collins; Sheldon L Morris
Journal:  Infect Immun       Date:  2002-07       Impact factor: 3.441

9.  Mixed infection and clonal representativeness of a single sputum sample in tuberculosis patients from a penitentiary hospital in Georgia.

Authors:  Isdore C Shamputa; Levan Jugheli; Nikoloz Sadradze; Eve Willery; Françoise Portaels; Philip Supply; Leen Rigouts
Journal:  Respir Res       Date:  2006-07-17

10.  Mycobacterium tuberculosis Beijing genotype, northern Malawi.

Authors:  Judith R Glynn; Amelia C Crampin; Hamidou Traore; Malcolm D Yates; Frank D Mwaungulu; Bagrey M Ngwira; Steven D Chaguluka; Donex T Mwafulirwa; Sian Floyd; Caroline Murphy; Francis A Drobniewski; Paul E M Fine
Journal:  Emerg Infect Dis       Date:  2005-01       Impact factor: 6.883

View more
  51 in total

1.  How host heterogeneity governs tuberculosis reinfection?

Authors:  M Gabriela M Gomes; Ricardo Aguas; João S Lopes; Marta C Nunes; Carlota Rebelo; Paula Rodrigues; Claudio J Struchiner
Journal:  Proc Biol Sci       Date:  2012-02-22       Impact factor: 5.349

2.  High burden of prevalent tuberculosis among previously treated people in Southern Africa suggests potential for targeted control interventions.

Authors:  Florian M Marx; Sian Floyd; Helen Ayles; Peter Godfrey-Faussett; Nulda Beyers; Ted Cohen
Journal:  Eur Respir J       Date:  2016-07-07       Impact factor: 16.671

Review 3.  Tuberculosis and HIV Coinfection.

Authors:  Judith Bruchfeld; Margarida Correia-Neves; Gunilla Källenius
Journal:  Cold Spring Harb Perspect Med       Date:  2015-02-26       Impact factor: 6.915

Review 4.  Metabolic Perspectives on Persistence.

Authors:  Travis E Hartman; Zhe Wang; Robert S Jansen; Susana Gardete; Kyu Y Rhee
Journal:  Microbiol Spectr       Date:  2017-01

5.  Tuberculosis along the continuum of HIV care in a cohort of adolescents living with HIV in Ethiopia.

Authors:  D Jerene; W Abebe; K Taye; P G Suarez; Y Feleke; I Hallström; A J Ruff
Journal:  Int J Tuberc Lung Dis       Date:  2017-01-01       Impact factor: 2.373

6.  23-valent pneumococcal polysaccharide vaccine elicits hierarchical antibody and cellular responses in healthy and tuberculosis-cured elderly, and HIV-1-infected subjects.

Authors:  Huichang Huang; Xiaohua Qian; Rong Pan; Ling Shen; Shanshan Liang; Feifei Wang; Peng Zhang; Hongbo Shen; Zheng W Chen
Journal:  Clin Immunol       Date:  2018-05-09       Impact factor: 3.969

Review 7.  Advancing host-directed therapy for tuberculosis.

Authors:  Robert S Wallis; Richard Hafner
Journal:  Nat Rev Immunol       Date:  2015-03-13       Impact factor: 53.106

Review 8.  A systematic review of published literature describing factors associated with tuberculosis recurrence in people living with HIV in Africa.

Authors:  Yoshan Moodley; Kumeren Govender
Journal:  Afr Health Sci       Date:  2015-12       Impact factor: 0.927

9.  The risk and timing of tuberculosis diagnosed in smear-negative TB suspects: a 12 month cohort study in Harare, Zimbabwe.

Authors:  Munyaradzi Dimairo; Peter MacPherson; Tsitsi Bandason; Abbas Zezai; Shungu S Munyati; Anthony E Butterworth; Stanley Mungofa; Simba Rusikaniko; Katherine Fielding; Peter R Mason; Elizabeth L Corbett
Journal:  PLoS One       Date:  2010-07-28       Impact factor: 3.240

10.  Decay kinetics of an interferon gamma release assay with anti-tuberculosis therapy in newly diagnosed tuberculosis cases.

Authors:  Ifedayo M O Adetifa; Martin O C Ota; Brigitte Walther; Abdulrahman S Hammond; Moses D Lugos; David J Jeffries; Simon A Donkor; Richard A Adegbola; Philip C Hill
Journal:  PLoS One       Date:  2010-09-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.